Today’s article acknowledges that the bad publicity generated by several high-profile drug price controversies – with the most recent involving Mylan and its EpiPen – as well as the political rhetoric surrounding these incidents – especially Hillary Clinton’s promise to tackle “price gouging” by pharmaceutical companies as president – have weighed on healthcare stocks over the last few years. So what should healthcare investors nervous about the impact of potential government interference and drug price cuts do? The answer may relate to a different kind of pricing mechanism that is gaining traction. To read more about this pricing model and what it may mean for healthcare stocks – as well as for two industries that still-wary investors may want to consider instead for healthcare exposure – CLICK HERE.